Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 04, 2026
Exact Sciences schedules third quarter 2021 earnings call
06:00am, Friday, 08'th Oct 2021
MADISON, Wis., Oct. 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its third quarter 2021 financial results after the close of the U.S.
The 1 Stock I'd Buy Right Now
07:05am, Saturday, 18'th Sep 2021
The pandemic isn't over yet.
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
12:00pm, Monday, 06'th Sep 2021
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and di
Exact Sciences to participate in September investor conferences
06:00am, Wednesday, 01'st Sep 2021
MADISON, Wis. , Sept. 1, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan
06:00am, Monday, 16'th Aug 2021
MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast Recurre
MADISON, Wis., Aug. 13, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) announced today that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-
Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer
08:27am, Saturday, 07'th Aug 2021
EXACT Sciences Corporation (NASDAQ: EXAS) reportedly approached Invitae Corp (NYSE: NVTA) for a potential merger. These are the details.
10 Stocks to Buy From Cathie Wood's Fleet of ETFs
10:45am, Friday, 06'th Aug 2021
The haters have come out against portfolio manager Cathie Wood. In fact, an ETF is preparing to launch that bets against her stocks to buy.
Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top
12:55pm, Thursday, 29'th Jul 2021
Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.
Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2021 Results - Earnings Call Transcript
11:49pm, Wednesday, 28'th Jul 2021
Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2021 Results - Earnings Call Transcript
Exact Sciences Announces Second Quarter 2021 Results
04:05pm, Wednesday, 28'th Jul 2021
MADISON, Wis., July 28, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $434.8 million for the second quarter ended June 30, 2021, compa
Bull of the Day: Exact Sciences (EXAS)
06:54am, Monday, 19'th Jul 2021
EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year
Where Will ARK Genomic Revolution ETF Be in 5 Years?
06:12am, Saturday, 10'th Jul 2021
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
Exact Sciences schedules second quarter 2021 earnings call
06:00am, Thursday, 08'th Jul 2021
MADISON, Wis., July 8, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its second quarter 2021 financial results after the close of the U.S.
Strong Revenue Trend Could Drive EXACT Sciences Corporation Stock To $160
05:00am, Friday, 18'th Jun 2021
Up around 2.5x from its low in March 2020, at the current price of $126 per share, we believe EXACT Sciences Corporation stock has further upside potential. EXAS, a molecular diagnostics company, has
